Elisabeth G.E. de Vries
Impact in
- Oncology top 0.01%
- Drug Transport and Resistance Mechanisms
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.1%
Papers in
- Oncology 443
- Drug Transport and Resistance Mechanisms 85
- HER2/EGFR in Cancer Research 66
-
- Cancer therapeutics and mechanisms 61
- Cell death mechanisms and regulation 51
- Co-authors
- Steven de Jong (105 shared papers)Jourik A. Gietema (86 shared papers)Nanno H. Mulder (97 shared papers)Marjolijn N. Lub–de Hooge (77 shared papers)Ido P. Kema (48 shared papers)Winette T.A. van der Graaf (71 shared papers)Pax H.B. Willemse (64 shared papers)Harry Hollema (61 shared papers)
- Journals
- Journal of Clinical Oncology (80 papers)European Journal of Cancer (45 papers)Annals of Oncology (41 papers)Journal of Nuclear Medicine (36 papers)British Journal of Cancer (33 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Elisabeth G.E. de Vries
958 papers receiving 45.0k citations
Elisabeth G.E. de Vries's Hit Papers
Peers
Comparison fields: 5 of 186
- Oncology 18.3k
- Cancer Research 4.7k
- Radiology, Nuclear Medicine and Imaging 6.1k
- Reproductive Medicine 1.5k
- Pulmonary and Respiratory Medicine 5.2k
Countries citing papers authored by Elisabeth G.E. de Vries
This map shows the geographic impact of Elisabeth G.E. de Vries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth G.E. de Vries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth G.E. de Vries more than expected).
Fields of papers citing papers by Elisabeth G.E. de Vries
This network shows the impact of papers produced by Elisabeth G.E. de Vries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth G.E. de Vries. The network helps show where Elisabeth G.E. de Vries may publish in the future.
Co-authors
The 25 scholars most cited alongside Elisabeth G.E. de Vries, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 977 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2096 |
| 2 | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Hit paper breakdown → | 2017 | 1580 |
| 3 | RECIST 1.1—Update and clarification: From the RECIST committee Hit paper breakdown → | 2016 | 1258 |
| 4 | Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer Hit paper breakdown → | 2010 | 641 |
| 5 | Evidence Based Selection of Housekeeping Genes Hit paper breakdown → | 2007 | 617 |
| 6 | Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Hit paper breakdown → | 1994 | 551 |
| 7 | A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Hit paper breakdown → | 2015 | 542 |
| 8 | A review on CXCR4/CXCL12 axis in oncology: No place to hide Hit paper breakdown → | 2012 | 519 |
| 9 | Radiolabeled amino acids: basic aspects and clinical applications in oncology. | 2001 | 449 |
| 10 | Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. | 1993 | 433 |
| 11 | Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Hit paper breakdown → | 2019 | 409 |
| 12 | ESMO-Magnitude of Clinical Benefit Scale version 1.1 Hit paper breakdown → | 2017 | 378 |
| 13 | 2000 | 353 | |
| 14 | 2018 | 348 | |
| 15 | 2010 | 316 | |
| 16 | 2002 | 299 | |
| 17 | Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer Hit paper breakdown → | 2016 | 294 |
| 18 | 2009 | 271 | |
| 19 | 2015 | 270 | |
| 20 | 2008 | 262 |
About Elisabeth G.E. de Vries
Elisabeth G.E. de Vries is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Epidemiology, having authored 977 papers that have together received 46.2k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (85 papers), Radiopharmaceutical Chemistry and Applications (68 papers), HER2/EGFR in Cancer Research (66 papers), Neuroendocrine Tumor Research Advances (61 papers), Cancer therapeutics and mechanisms (61 papers), Cell death mechanisms and regulation (51 papers), Monoclonal and Polyclonal Antibodies Research (46 papers) and Medical Imaging Techniques and Applications (46 papers). The work is most often cited by research in Oncology (18.3k citations), Cancer Research (4.7k citations), Radiology, Nuclear Medicine and Imaging (6.1k citations), Reproductive Medicine (1.5k citations) and Pulmonary and Respiratory Medicine (5.2k citations). Elisabeth G.E. de Vries has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Steven de Jong, Jourik A. Gietema, Nanno H. Mulder, Marjolijn N. Lub–de Hooge, Ido P. Kema, Winette T.A. van der Graaf, Pax H.B. Willemse, Harry Hollema, Hetty Timmer‐Bosscha and Adrienne H. Brouwers. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Journal of Nuclear Medicine and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.